C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2026)

C4 Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $61.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 1679.67% year-over-year to $61.3 million in Q1 2026; TTM through Mar 2026 was $61.3 million, a 1679.67% increase from a year earlier, with the FY2025 full-year figure at $74.6 million, up 34.42% from the prior year.
• Cash & Equivalents declined to $61.3 million in Q1 2026 per CCCC's latest filing, from $74.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $78.2 million in Q2 2025 and bottomed at $3.3 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $3.5 million (2023), against an average of $29.9 million.
• Across the five-year window, Cash & Equivalents surged 4390.28% in 2022 and tumbled 94.23% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $3.3 million in 2022, then advanced by 5.0% to $3.4 million in 2023, then soared by 1511.94% to $55.5 million in 2024, then jumped by 34.42% to $74.6 million in 2025, then slipped by 17.87% to $61.3 million in 2026.
• Per Business Quant, the three latest CCCC Cash & Equivalents figures stand at $61.3 million (Q1 2026), $74.6 million (Q4 2025), and $3.4 million (Q3 2025).